期刊
CRITICAL REVIEWS IN CLINICAL LABORATORY SCIENCES
卷 51, 期 6, 页码 305-320出版社
TAYLOR & FRANCIS LTD
DOI: 10.3109/10408363.2014.937522
关键词
Atherosclerosis; metabolic syndrome; microRNAs
资金
- National Institutes of Health [R01HL107953, R01HL106063]
- Foundation Leduqc Network of Excellence in Cardiovascular Research
Metabolic syndrome is a complex metabolic condition caused by abnormal adipose deposition and function, dyslipidemia and hyperglycemia, which affects >47 million American adults and similar to 1 million children. Individuals with the metabolic syndrome have essentially twice the risk for developing cardiovascular disease (CVD) and Type 2 diabetes mellitus (T2D), compared to those without the syndrome. In the search for improved and novel therapeutic strategies, microRNAs (miRNA) have been shown to be interesting targets due to their regulatory role on gene networks controlling different crucial aspects of metabolism, including lipid and glucose homeostasis. More recently, the discovery of circulating miRNAs suggest that miRNAs may be involved in facilitating metabolic crosstalk between organs as well as serving as novel biomarkers of diseases, including T2D and atherosclerosis. These findings highlight the importance of miRNAs for regulating pathways that underlie metabolic diseases, and their potential as therapeutic targets for the development of novel treatments.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据